Impax Loses Bid For Generic Version Of Rilutek

Law360 (September 1, 2004, 12:00 AM EDT) -- Impax Laboratories Inc.'s proposed generic version of Rilutek infringes on Aventis SA's patent for the brand version of the drug, a U.S. federal court has ruled.

In its decision, Judge Joseph J. Farnan Jr. of the U.S. District Court for the District of Delaware ruled that Aventis Pharmaceutical's patent 5,527,814 related to the use of Rilutek is valid, enforceable and infringed by IMPAX's proposed generic product.

Impax had received approval from the Food and Drug Administration for its version of the drug, Riluzole 50mg, in January...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.